Cancer News and Research

Latest Cancer News and Research

CytomX Therapeutics completes $30 million Series B financing

CytomX Therapeutics, a biotechnology company focused on the development of proteolytically-activated antibodies, today announced it has completed a $30 million Series B financing.

23 Sep 2010

Tolerx presents otelixizumab preclinical research at 46th EASD

Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today announced the presentation of preclinical research describing the mechanism of action of otelixizumab at the 46th Annual Meeting of the European Association for the Study of Diabetes (EASD). In addition, Tolerx also announced that the first European patient was enrolled in DEFEND-2, a confirmatory Phase 3 clinical trial evaluating otelixizumab in autoimmune new-onset type 1 diabetes.

23 Sep 2010

FDA grants ZIOPHARM's darinaparsin Orphan Drug Designation for peripheral T-cell Lymphoma treatment

ZIOPHARM Oncology, Inc. announced today that the United States Food & Drug Administration (FDA) has granted Orphan Drug Designation to darinaparsin (Zinapar™ or ZIO-101) for the treatment of peripheral T-cell Lymphoma (PTCL). The United States Orphan Drug Act of 1983 was created to provide incentives for companies to develop and market treatments for diseases or conditions affecting fewer than 200,000 people in the United States.

23 Sep 2010

Vertex Pharmaceuticals agrees to sell 3.35% convertible senior subordinated notes due 2015

Vertex Pharmaceuticals Incorporated today announced that it has entered into an agreement to sell $375.0 million aggregate principal amount of 3.35% convertible senior subordinated notes due 2015.

23 Sep 2010

MDS Nordion, Isotope enter framework agreement

MDS Nordion, a leading provider of products and services to the global health science market, today announced it has entered into a framework agreement with The Open Joint Stock Company "Isotope" the authorized subsidiary of Rosatom State Corporation, to explore and define areas of collaboration in the field of supply, marketing and sale of isotopes produced in Russia.

23 Sep 2010

Golden Helix refactors HSPH's software for studying disease heritability in families

Today, Golden Helix, Inc., a global leader in genetic analysis solutions, announced a collaboration with Harvard School of Public Health (HSPH) under which Golden Helix is refactoring PBAT, HSPH's software for studying disease heritability in families.

23 Sep 2010

Raltegravir could be valid target against all Herpesviridae

Scientists at the Institute for Research in Biomedicine (IRB Barcelona) headed by the coordinator of the Structural and Computational Biology Programme, Miquel Coll, have published a new study that demonstrates that raltegravir, the drug approved in 2007 for the treatment of AIDS that is sold by Merck under the name Isentress, cancels the function of an essential protein for the replication of one kind of herpes virus.

23 Sep 2010

New iPhone application for breast cancer patients

Nonprofit Breastcancer.org has launched an iPhone application for breast cancer patients. The Breast Cancer Diagnosis Guide is a free mobile app that walks users through the breast cancer pathology report a vital report that sets the patient's treatment path.

23 Sep 2010

Elsevier's new online surgical journal publishes case reports

Elsevier, the world-leading publisher of scientific, technical and medical information products and services together with Surgical Associates Ltd the Owner of the International Journal of Surgery, announced today the launch of the International Journal of Surgery Case Reports (IJSCR) a new author-pays online general surgical journal dedicated to publishing case reports only.

23 Sep 2010

New interactive source of mammography launched

Women confused about when to have a mammogram have a new interactive source of information — MammographySavesLives.org — launching this week along with a series of public service announcements on television and radio stations across the country.

23 Sep 2010

Scientists to develop methotrexate nose drops for brain cancer

Scientists are reporting the development and successful initial testing of a new form of methotrexate the mainstay anticancer drug designed to be given as nose drops rather than injected. It shows promise as a more effective treatment for brain cancer, they say. The report appears in ACS' Molecular Pharmaceutics, a bi-monthly journal.

23 Sep 2010

Asuragen announces results of study evaluating RNA-based assay for detection of common NPM1 mutations

Asuragen, Inc. announced today the results of a collaborative study with scientists at Johns Hopkins University School of Medicine evaluating a RNA-based assay for the rapid, sensitive and multiplex detection of common NPM1 mutations. The study results were published in the September issue of the Journal of Molecular Diagnostics.

23 Sep 2010

Data shows preoperative Web-based interactive programs reduce hospital stays

Patients who participate in Web-based interactive programs prior to surgery have a significantly shorter length of stay than those who do not, according to new data. Preoperative education reinforces messages about care instructions and safety, and reduces the level of stress patients experience after their procedure - leading to improved efficiency and care.

23 Sep 2010

New study calls future parents to understand effects of perinatal events on child development

Approximately 5,000 families (pregnant women, fathers and newborns) are being asked to take part in a new study called Étude 3-D (Découvrir, Développer, Devenir) that is aimed at understanding the effects of perinatal events on child development. The study is directed by Dr. William Fraser, Associate Director of Clinical Research at the CHU Sainte-Justine and professor of Medicine at the University of Montreal.

23 Sep 2010

Novartis applauds declaration of CML Awareness Day in Canada

Today is a meaningful milestone for chronic myelogenous leukemia (CML) patients and their families.

23 Sep 2010

Texas grapples with medical malpractice reform while Illinois addresses employer health care costs

Texas Tribune: "As a federal judge considers the constitutionality of Texas' 2003 medical malpractice reform — and Gov. Rick Perry campaigns for more lawsuit restrictions — the Texas Supreme Court has narrowly ruled that hospital injuries seemingly unrelated to doctor error can still fall under the state's stringent medical malpractice caps.

23 Sep 2010

NCI selects Caliper's Quantum FX microCT system to study tumor models in lung cancer

Caliper Life Sciences, Inc., a leading provider of tools and services for drug discovery and life sciences research, today announced that the National Cancer Institute has purchased Caliper's Quantum FX, a stand-alone microCT system for pre-clinical imaging, to study spontaneous tumor models in lung cancer.

23 Sep 2010

University of Illinois at Chicago receives $12.4M grant to study smoking behaviors in young adults

The University of Illinois at Chicago has received a $12.4 million grant from the National Cancer Institute to study the predictors of smoking patterns from adolescence through young adulthood.

23 Sep 2010

Revolutionary technology 'cooks' brain tumor

University Hospitals (UH) Case Medical Center is offering new hope for patients with inoperable brain tumors or lesions previously diagnosed as untreatable through a revolutionary technology called AutoLITT which "cooks" brain tumors with an MRI-guided laser. UH becomes one of only three medical centers in the world offering AutoLITT as part of its arsenal in the fight against cancer. It is especially effective in treating glioblastoma, one of the most aggressive and difficult-to-treat brain cancers.

23 Sep 2010

FDA and EMA accept regulatory submissions of vandetanib for advanced medullary thyroid cancer

AstraZeneca today announced that the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted regulatory submissions for review of the investigational drug vandetanib in the treatment of patients with advanced medullary thyroid cancer (MTC). The FDA also granted priority review status for the new drug application and set a Prescription Drug User Fee Act (PDUFA) action date of 7 January 2011.

23 Sep 2010

Cancer News and Research

Latest Cancer News and Research

CytomX Therapeutics completes $30 million Series B financing

Tolerx presents otelixizumab preclinical research at 46th EASD

FDA grants ZIOPHARM's darinaparsin Orphan Drug Designation for peripheral T-cell Lymphoma treatment

Vertex Pharmaceuticals agrees to sell 3.35% convertible senior subordinated notes due 2015

MDS Nordion, Isotope enter framework agreement

Golden Helix refactors HSPH's software for studying disease heritability in families

Raltegravir could be valid target against all Herpesviridae

New iPhone application for breast cancer patients

Elsevier's new online surgical journal publishes case reports

New interactive source of mammography launched

Scientists to develop methotrexate nose drops for brain cancer

Asuragen announces results of study evaluating RNA-based assay for detection of common NPM1 mutations

Data shows preoperative Web-based interactive programs reduce hospital stays

New study calls future parents to understand effects of perinatal events on child development

Novartis applauds declaration of CML Awareness Day in Canada

Texas grapples with medical malpractice reform while Illinois addresses employer health care costs

NCI selects Caliper's Quantum FX microCT system to study tumor models in lung cancer

University of Illinois at Chicago receives $12.4M grant to study smoking behaviors in young adults

Revolutionary technology 'cooks' brain tumor

FDA and EMA accept regulatory submissions of vandetanib for advanced medullary thyroid cancer

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Cancer News and Research

Latest Cancer News and Research

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Newsletters you may be interested in